Filter By:
Viewing 1 to 8 (8 Total)

Selumetinib

09/28/2014

ESMO Congress 2014 - Madrid, Spain

A Phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC

E. Dean, et al.

Selumetinib

06/02/2014

American Society of Clinical Oncology Meeting

A Phase I Study of the MEK1 Inhibitor Selumetinib (AZD6244) Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PNs)

L. Marcus, et al.

Selumetinib

06/08/2013

Children’s Tumor Foundation’s Neurofibromatosis Conference

A Phase I Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib) in Children and Young Adults with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibromas (PN)

B. Widemann, MD, et al.

Selumetinib

06/01/2013

American Society of Clinical Oncology Annual Meeting

Phase II Study of Selumetinib vs Temozolomide in Patients with Advanced Uveal Melanoma (CTEP #8443)

R. D. Carvajal

Selumetinib

12/21/2012

The Lancet Oncology

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

J. Farley, et al.

Selumetinib

11/28/2012

The Lancet Oncology

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

P. A. Janne, et al.

Selumetinib

06/04/2012

American Society of Clinical Oncology Annual Meeting

Reacquisition of RAI incorporation of RAI - refractory metastatic thyroid cancers by pretreatment with the selective MEK inhibitor Selumetinib (AZD6244): A pilot study (NCT00970359)

A. L. Ho, et al.

Selumetinib

04/02/2012

American Association for Cancer Research Annual Meeting

A PHASE II TRIAL OF SELUMETINIB (AZD6244; ARRY-142886) IN WOMEN WITH RECURRENT LOW-GRADE SEROUS CARCINOMA OF THE OVARY OR PERITONEUM: A Gynecologic Oncology Group Study

J. Farley, et al.